financial analysis nobel biocare holding ag develops and produces dental implants and dental...
Post on 14-Jul-2015
163 Views
Preview:
TRANSCRIPT
20.02.2013
Ticker: Nobel Biocare Holding AG Benchmark:
Currency: SIX Swiss Ex: NOBN, Currency: CHF SWISS MARKET INDEX (SMI)
Sector: Health Care Industry: Health Care Equipment & Suppli Year:
Telephone 41-43-211-4200 Revenue (M) Business Segments in CHF Sales (M) Geographic Segments in CHF Sales (M)
Website www.nobelbiocare.com No of Employees Dental Implants 700 EMEA 277
Address PO Box CH-8058 Zurich-Airport Glattbrugg, 8152 Switzerland Reconciliation 0 Americas 275
Share Price Performance in CHF Asia/Pacific 147
Price 9.13 1M Return -3.9% Reconciliation 0
52 Week High 11.68 6M Return -1.6% Rest of the World
52 Week Low 7.09 52 Wk Return -21.1% North America
52 Wk Beta 1.27 YTD Return 17.7%
Credit Ratings
Bloomberg IG1
S&P - Date - Outlook -
Moody's - Date - Outlook -
Fitch - Date - Outlook -
Valuation Ratios
12/09 12/10 12/11 12/12 12/13E 12/14E 12/15E
P/E 27.2x 38.3x 28.1x 17.4x 18.8x 16.4x 12.7x
EV/EBIT 20.3x 20.5x 15.5x 10.7x - - -
EV/EBITDA 17.0x 15.2x 10.7x 7.3x 8.5x 7.9x 7.1x
P/S 5.0x 3.0x 1.9x 1.4x 1.6x 1.5x 1.5x
P/B 9.1x 5.4x 3.9x 2.4x 2.7x 2.5x 2.2x
Div Yield 1.6% 2.5% 1.7% 2.5% 2.3% 2.7% 3.1%
Profitability Ratios %
12/09 12/10 12/11 12/12 12/13E 12/14E 12/15E
Gross Margin 80.5 77.7 76.0 75.4 75.5 75.7 76.1
EBITDA Margin 29.1 19.9 18.4 17.4 17.7 18.5 19.4
Operating Margin 24.4 14.7 12.7 11.8 11.7 12.6 14.1
Profit Margin 18.2 7.9 7.0 7.9 8.7 9.5 11.1
Return on Assets 14.9 6.1 5.8 7.7 8.7 9.2 10.0
Return on Equity 36.2 14.3 13.2 15.1 16.3 17.2 16.7
Leverage and Coverage Ratios
12/09 12/10 12/11 12/12
Current Ratio 3.2 1.0 1.5 2.2 Current Capitalization in CHF
Quick Ratio 2.9 0.9 1.3 1.9 Common Shares Outstanding (M) 122.8
EBIT/Interest 8.8 4.8 5.0 13.5 Market Capitalization (M) 1130.2
Tot Debt/Capital 0.4 0.4 0.3 0.2 Cash and ST Investments (M) 187.0
Tot Debt/Equity 0.8 0.8 0.5 0.3 Total Debt (M) 120.1
Eff Tax Rate % 22.9 54.5 28.3 24.8 Preferred Equity (M) 0.0
LT Investments in Affiliate Companies (M) 0.0
Investments (M) 0.0
Enterprise Value (M) 1063.2
Nobel Biocare Holding AG develops and produces dental implants and dental
prosthetics. The Company manufactures permanent replacements for tooth roots, and
dental crowns and bridges. Nobel Biocare sells under the brand names Branemark
System, Steri-Oss/Replace, and Procera on the global market.
NOBN SW
700
2'496
Company Analysis - Overview
100%
0%
AbkqUi FjmiUkqp ObZlkZfifUqflk
40%
39%
21%
0%
BJB5 5jbofZUp
5pfU%MUZfcfZ ObZlkZfifUqflk
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |
Nobel Biocare Holding AG
Target price in CHF
Date Buy Hold Sell Date Price Target Price Broker Analyst Recommendation Target Date
0.!GXk!.0 1% 13% 2-% /-!CbY!.0 6%.0 5%36 AbrqpZeb 8Xkg VF!A7K T7KD pbhh 2%6- /-!CbY!.00.!AbZ!./ 5% 1/% 2-% .6!CbY!.0 6%3. 5%6. DlhaiXk PXZep SBOLKFH7 AR87GLS7 kbrqoXh&kbrqoXh 6%/- /-!CbY!.00-!Kls!./ 5% 1/% 2-% .5!CbY!.0 6%60 5%6. 9obafq Prfppb 9EOFPQLME DOBQIBO kbrqoXh .-%5- /-!CbY!.00.!LZq!./ 5% 1/% 2-% .2!CbY!.0 6%3/ 5%6. 8bobkYbod 8Xkg QLJ GLKBP Yrv ./%/2 /-!CbY!.0/5!Pbm!./ ./% 1/% 13% .1!CbY!.0 6%3/ 5%25 Hbmhbo 9XmfqXh JXogbqp J7G7 M7Q7HF elha 6%0- /-!CbY!.00.!7rd!./ .0% 13% 1/% .0!CbY!.0 6%45 5%25 P M 9XmfqXh FN G79L8 QEO7KB pbhh 5%3- /-!CbY!.00.!Grh!./ .4% 05% 13% ./!CbY!.0 6%11 5%1/ JXfk Cfopq 8Xkg 7D PQBME7K SLIIBOQ rkabombocloi 5%5- /-!CbY!.0/6!Grk!./ .4% 05% 13% ..!CbY!.0 6%05 5%1/ BuXkb 8KM MXofYXp GRIFBK ALOJLFP rkabombocloi 6%-- /-!CbY!.00.!JXv!./ .4% 1/% 1/% 5!CbY!.0 6%01 5%30 8XoZhXvp 7IBU7KABO HIB87K rkabotbfdeq 3%3- /-!CbY!.00-!7mo!./ /.% 00% 13% 4!CbY!.0 6%.2 5%30 JlodXk PqXkhbv JF9E7BI H GRKDIFKD Rkabotq&7qqoXZqfsb 2%6- .6!CbY!.00-!JXo!./ /.% 00% 13% 3!CbY!.0 6%00 5%30 GMJlodXk A7SFA G 7AIFKDQLK rkabotbfdeq 4%0- .6!CbY!.0/6!CbY!./ .4% 05% 13% 2!CbY!.0 6%/5 5%30 PXkcloa 9% 8bokpqbfk 9l IFP7 8BABII 9IFSB iXogbq mbocloi 6%-- .6!CbY!.0
1!CbY!.0 6%.4 5%30 8Xkg SlkqlYbh 7D 97OI7 87BKWFDBO elha 5%3- .6!CbY!.0.!CbY!.0 6%13 5%30 8ovXk DXokfbo 9fb J7QEFBR 9E78BOQ pbhh 5%6- .6!CbY!.0
0.!GXk!.0 6%21 5%30 KliroX J7OQFK 8ORKKFKDBO kbrqoXh .-%-- .6!CbY!.00-!GXk!.0 6%25 5%23 EbhsbX PFJLK DLBQP9EJ7KK kbrqoXh 6%4- .6!CbY!.0/6!GXk!.0 6%25 5%2/ KloqeZlXpq ObpbXoZe BATFK PKVABO pbhh 3%2- .6!CbY!.0/5!GXk!.0 6%36 5%2/ 9liibowYXkg 9lomloXqbp JXogbqp LIFSBO JBQWDBO elha 6%.- .2!CbY!.0/2!GXk!.0 6%4. 5%2/ EP89 EBKAOFH ILCORQEB kbrqoXh 6%-- .2!CbY!.0/1!GXk!.0 6%4- 5%2/ BS7 Afibkpflkp 7KAOBT P W7JCLQFP rkabotbfdeq /0!GXk!.0/0!GXk!.0 6%6- 5%2/ WrboZebo HXkqlkXhYXkg PF8VIIB 8FP9ELC8BODBO COF9H rkabombocloi .3!GXk!.0//!GXk!.0 6%11 5%1- 97 9ebrsobru A7KFBI GBILS97K rkabombocloi 4%/2 5!Kls!.//.!GXk!.0 6%1/ 5%1- Gbccbofbp FKDB8LOD LFB elha 6%-- .2!LZq!./.5!GXk!.0 6%2- 5%1- BnrfqX PFJ Pm7 C78FL C7WW7OF klq oXqba /3%-- /.!JXv!-6.4!GXk!.0 6%-2 5%1-.3!GXk!.0 5%36 5%1-.2!GXk!.0 5%4- 5%10.1!GXk!.0 5%3- 5%10..!GXk!.0 5%32 5%10.-!GXk!.0 5%32 5%10
Company Analysis - Analysts Ratings
6rt RkT Bagg 8aSliiakTRodlkn sn 7mdSa RkT PRmcao 7mdSa
%4% '%% '%% %4% %4% %4% %0% %'% 5% 5% 5% 1%
05% 00% 00% 1'% 05% 05% 13% 1'%1'% 1'% 1'% 13%
13% 13% 13% 1'% 13% 13% 1'% 13% 2!% 2!% 2!% 2!%
&%
/&%
1&%
3&%
4&%
.&&%
cxso!./ jUop!./ Uso!./ jUf!./ grfk!./ grfi!./ Ulyq!./ pbmq!./ lZq!./ kls!./ axZ!./ gUks!.0
6ol
hbo O
bZlj
jbk
aUqfl
k
&
/
1
3
4
.&
./
.1
.3 MofZ
b
6rv Elia Pbii MofZb QUodbq MofZb
6mleamn PRmcao 7mdSa
&
2
.&
.2
/&
/2
0&
Abr
qpZe
b 6
Ukh
Dli
ajUk
PUZ
ep
8ob
afq P
rfpp
b
6bo
bkVb
od 6
Ukh
Hbm
ibo 8
UmfqU
i JUo
hbqp
P
M 8
UmfqU
i FN
JUf
k Cf
opq 6
Ukh
5D
BuU
kb 6
KM
MUo
fVUp
6Uo
ZiUv
p
Jlo
dUk
PqU
kibv
GMJ
lodU
k
PUk
cloa
8! 6
bokp
qbfk
8
l
6Uk
h S
lkql
Vbi 5
D
6ov
Uk D
Uokf
bo
8fb
Klj
roU
Ebi
sbU
Klo
qeZl
Upq O
bpbU
oZe
8lj
jbo
wVUk
h 8
loml
oUqb
p
JUo
hbqp
EP
68
BS
5 A
fjbk
pflk
p
Trbo
Zebo
HUk
qlkU
iVUk
h
85
8eb
rsob
ru
Gbccb
ofbp
Bnr
fqU P
FJ P
m5
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |
20.02.2013
Nobel Biocare Holding AG
Ownership Statistics Geographic Ownership Distribution
Shares Outstanding (M) 122.8 United States 29.78%
Float 87.0% Britain 24.96%
Short Interest (M) Switzerland 10.66%
Short Interest as % of Float Singapore 9.98%
Days to Cover Shorts Canada 8.38%
Institutional Ownership 54.70% Norway 5.69%
Retail Ownership 45.07% Luxembourg 5.32%
Insider Ownership 0.23% Others 5.23%
Institutional Ownership Distribution
Investment Advisor 62.78%
Government 15.52%
Mutual Fund Manager 10.29%
Other 5.74%
Pricing data is in CHF Others 5.66%
Top 20 Owners:
Holder Name Position Position Change Market Value % of Ownership Report Date Source Country
SILCHESTER INTL INVE 12'605'473 6'383'119 115'087'968 10.18% 24.08.2012 EXCH BRITAIN
FRANKLIN RESOURCES 7'387'481 72'834 67'447'702 5.97% 14.01.2013 ULT-AGG UNITED STATES
GOVT OF SINGAPORE IN 6'795'557 0 62'043'435 5.49% 31.12.2011 ULT-AGG SINGAPORE
INVESCO LTD 6'216'059 2'445'504 56'752'619 5.02% 11.04.2012 EXCH UNITED STATES
TRIMARK INVESTMENT M 5'030'544 0 45'928'867 4.06% 30.09.2012 MF-AGG CANADA
GOVERNANCE FOR OWNER 3'909'643 0 35'695'041 3.16% 31.12.2011 Co File BRITAIN
NORGES BANK 3'768'834 0 34'409'454 3.04% 05.02.2013 EXCH NORWAY
CREDIT SUISSE ASSET 2'500'726 -42'449 22'831'628 2.02% 28.12.2012 MF-AGG SWITZERLAND
VANGUARD GROUP INC 2'274'825 21'757 20'769'152 1.84% 31.12.2012 MF-AGG UNITED STATES
NEW JERSEY DIVISION 2'183'120 0 19'931'886 1.76% 30.06.2012 MF-AGG UNITED STATES
UNION INVESTMENT GMB 2'000'000 -232'723 18'260'000 1.62% 28.09.2012 MF-AGG GERMANY
CAPITAL GROUP COMPAN 1'350'000 0 12'325'500 1.09% 31.12.2012 ULT-AGG UNITED STATES
SWISSCANTO FONDSLEIT 1'325'169 -51'431 12'098'793 1.07% 30.11.2012 MF-AGG SWITZERLAND
UNION INVESTMENT LUX 1'323'847 0 12'086'723 1.07% 28.09.2012 MF-AGG LUXEMBOURG
NOBEL BIOCARE HOLDIN 1'303'120 0 11'897'486 1.05% 31.12.2011 Co File SWITZERLAND
PICTET & CIE 681'647 1'555 6'223'437 0.55% 31.10.2012 MF-AGG SWITZERLAND
UBS FUND MANAGEMENT 670'183 1'761 6'118'771 0.54% 31.10.2012 MF-AGG SWITZERLAND
INVESCO CANADA LTD 565'501 0 5'163'024 0.46% 30.09.2012 MF-AGG CANADA
SCHRODER INVESTMENT 529'332 -192'242 4'832'801 0.43% 31.10.2012 MF-AGG BRITAIN
FMR LLC 427'359 427'359 3'901'788 0.35% 30.04.2012 ULT-AGG UNITED STATES
Top 5 Insiders:
Holder Name Position Position Change Market Value % of Ownership Report Date Source
LAUBE RICHARD T 110'000 1'004'300 0.09% 31.12.2011 Co File
BREU RAYMUND 70'000 639'100 0.06% 31.12.2011 Co File
WATTER ROLF URS 53'500 488'455 0.04% 31.12.2011 Co File
LILJA ROBERT 18'375 167'764 0.02% 31.12.2011 Co File
FLURI EDGAR 16'500 150'645 0.01% 31.12.2011 Co File
Company Analysis - Ownership
Ownership Type
55%
45%
0%
FkpqfqrqflkUi Ltkbopefm ObqUfi Ltkbopefm Fkpfabo Ltkbopefm
Geographic Ownership
30%
5%
11%
8%
10%
6%
5%
25%
Rkfqba PqUqbp 6ofqUfk PtfqwboiUka PfkdUmlob8UkUaU KlotUv IrubjVlrod Lqebop
Institutional Ownership
62%
10%
6%
6%
16%
Fksbpqjbkq 5asfplo Dlsbokjbkq JrqrUi Crka JUkUdboLqebo Lqebop
TOP 20 ALL
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |
Nobel Biocare Holding AG
Financial information is in CHF (M)
Periodicity: 12/02 12/03 12/04 12/05 12/06 12/07 12/08 12/09 12/10 12/11 12/12 12/13E 12/14E 12/15E
Income Statement
Revenue 456 508 600 750 945 1'094 982 878 796 702 700 705 731 770
- Cost of Goods Sold 111 120 122 133 151 175 199 171 178 168 172
Gross Income 345 388 478 617 794 919 783 706 619 533 527 532 553 586
- Selling, General & Admin Expenses 242 255 291 364 452 548 572 493 501 444 444
(Research & Dev Costs) 19 21 22 26 28 37 52 38 44 36 42
Operating Income 103 133 190 270 342 371 211 214 117 89 83 83 92 109
- Interest Expense 4 5 3 4 3 6 28 24 24 18 6
- Foreign Exchange Losses (Gains) 1 0 13 19 16 4 -97 -40 -44 -36 -0
- Net Non-Operating Losses (Gains) 9 -11 -5 -44 4 12 27 23 -2 39 4
Pretax Income 90 139 179 292 319 348 253 207 139 68 74 80 91 110
- Income Tax Expense 34 28 37 52 70 75 79 47 76 19 18
Income Before XO Items 56 111 142 239 249 273 174 160 63 49 55
- Extraordinary Loss Net of Tax 0 0 0 0 0 0 0 0 0
- Minority Interests 1 1 1 0 0 0 0 0 0 0 0
Diluted EPS Before XO Items 1.09 1.85 1.98 2.20 1.43 1.28 0.51 0.39 0.45
Net Income Adjusted* 55 109 147 201 249 273 184 160 109 49 59 61 70 85
EPS Adjusted 0.44 0.87 1.15 1.57 1.99 2.21 1.50 1.30 0.88 0.39 0.47 0.49 0.56 0.72
Dividends Per Share 0.15 0.26 0.53 0.70 0.85 0.95 0.59 0.55 0.48 0.18 0.19 0.21 0.24 0.29
Payout Ratio % 34.8 29.5 74.5 58.7 44.0 46.2 41.7 42.4 95.0 46.3 43.6 0.44 0.44 0.40
Total Shares Outstanding 126 127 129 126 124 122 123 123 123 122 123
Diluted Shares Outstanding 132 132 130 130 126 124 122 124 123 123 123
EBITDA 135 163 221 290 366 399 256 256 158 129 121 125 135 149
*Net income excludes extraordinary gains and losses and one-time charges.
Equivalent Estimates
Company Analysis - Financials I/IV
Fiscal Year
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |
Periodicity: 12/02 12/03 12/04 12/05 12/06 12/07 12/08 12/09 12/10 12/11 12/12 12/13E 12/14E 12/15E
Balance Sheet
Total Current Assets 206.207909 331.12563 463.403059 500.117142 492.379793 762.130423 629.90881 626.598869 532.918185 325.679126 365.411287
+ Cash & Near Cash Items 76 171 301 201 213 312 246 358 299 131 177
+ Short Term Investments 0 0 54 0 82 6 15 9 10
+ Accounts & Notes Receivable 77 92 110 163 200 253 211 203 166 133 116
+ Inventories 41 35 27 47 49 59 55 30 29 29 25
+ Other Current Assets 12 33 25 35 31 139 37 30 23 24 38
Total Long-Term Assets 265 259 263 302 319 324 410 445 430 395 359
+ Long Term Investments 1 1 1 3 4 3 0
Gross Fixed Assets 104 126 136 159 180 204 215 239 241 251 249
Accumulated Depreciation 64 82 86 94 102 110 109 127 128 146 164
+ Net Fixed Assets 40 44 49 66 78 94 106 112 113 105 86
+ Other Long Term Assets 224 214 213 234 237 227 304 332 317 290 274
Total Current Liabilities 78 97 120 201 185 270 213 198 519 212 163
+ Accounts Payable 20 14 20 29 51 49 42 33 24 19 23
+ Short Term Borrowings 2 0 1 2 3 42 3 315 45 0
+ Other Short Term Liabilities 56 83 100 171 131 217 128 162 179 148 140
Total Long Term Liabilities 81 48 56 45 46 373 429 402 45 166 170
+ Long Term Borrowings 43 1 1 0 0 342 356 351 0 120 120
+ Other Long Term Borrowings 37 46 55 45 46 31 72 51 45 47 50
Total Liabilities 159 144 176 246 231 643 641 600 563 378 333
+ Long Preferred Equity 0 0 0 0 0 0 0 0 0 0 0
+ Minority Interest 3 4 2 0 0 0 0 0 0 0 0
+ Share Capital & APIC 135 175 188 205 247 365 322 294 228 174 169
+ Retained Earnings & Other Equity 174 267 361 352 334 78 77 177 171 169 223
Total Shareholders Equity 312 446 551 557 581 444 399 471 399 342 392
Total Liabilities & Equity 471 590 727 803 811 1'086 1'040 1'071 963 721 725
Book Value Per Share 2.46 3.47 4.27 4.42 4.67 3.64 3.24 3.83 3.25 2.80 3.19 3.34 3.64 4.22
Tangible Book Value Per Share 2.79 2.72 2.91 1.95 0.99 1.33 0.98 0.68 1.17
Company Analysis - Financials II/IV
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |
Periodicity: 12/02 12/03 12/04 12/05 12/06 12/07 12/08 12/09 12/10 12/11 12/12 12/13E 12/14E 12/15E
Cash Flows
Net Income 55 109 141 239 249 273 174 160 63 49 55 61 71 86
+ Depreciation & Amortization 32 30 31 20 24 28 45 42 41 40 39
+ Other Non-Cash Adjustments 24 1 43 -37 7 -4 -12 17 5 -0 2
+ Changes in Non-Cash Capital -11 -13 -10 -53 -27 -76 56 39 17 21 21
Cash From Operating Activities 100 128 205 170 254 222 263 258 126 110 117
+ Disposal of Fixed Assets 0 0
+ Capital Expenditures -16 -19 -25 -30 -31 -41 -48 -28 -32 -21 -9 -30 -31 -36
+ Increase in Investments -54
+ Decrease in Investments
+ Other Investing Activities -4 5 -26 46 42 -120 -50 -43 2 -39 0
Cash From Investing Activities -20 -14 -51 -39 11 -161 -98 -71 -30 -60 -9
+ Dividends Paid -12 -20 -33 -68 -88 -106 -117 -68 -64 -41 -18
+ Change in Short Term Borrowings 22 -38 -2 -284 -45
+ Increase in Long Term Borrowings 7 0 382 0 118
+ Decrease in Long Term Borrowings -33 -42 -1 0 -18 -49
+ Increase in Capital Stocks 1 39 13 17 41 248 50 8 0 3
+ Decrease in Capital Stocks -182 -214 -486 -26 -10 -7 -6
+ Other Financing Activities -3 -4 -2 -0 0 -9 -130 55 24 0 -1
Cash From Financing Activities -39 -27 -22 -234 -260 30 -201 -70 -98 -213 -61
Net Changes in Cash 41 87 132 -103 5 91 -36 117 -2 -163 47
Free Cash Flow (CFO-CAPEX) 84 108 180 139 222 181 215 230 94 89 108 66 78 86
Free Cash Flow To Firm 86 112 183 142 224 186 234 249 105 102 112
Free Cash Flow To Equity 58 67 138 222 563 236 175 43 -77
Free Cash Flow per Share 0.67 0.86 1.41 1.09 1.78 1.46 1.76 1.87 0.76 0.73 0.88
Company Analysis - Financials III/IV
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |
Periodicity: 12/02 12/03 12/04 12/05 12/06 12/07 12/08 12/09 12/10 12/11 12/12 12/13E 12/14E 12/15E
Ratio Analysis
Valuation Ratios
Price Earnings 40.8x 28.1x 37.2x 30.7x 35.3x 27.1x 16.0x 27.2x 38.3x 28.1x 17.4x 18.8x 16.4x 12.7x
EV to EBIT 21.6x 22.2x 26.2x 25.9x 25.0x 19.8x 13.7x 20.3x 20.5x 15.5x 10.7x
EV to EBITDA 16.5x 18.0x 22.6x 24.1x 23.3x 18.4x 11.3x 17.0x 15.2x 10.7x 7.3x 8.5x 7.9x 7.1x
Price to Sales 4.9x 6.1x 8.8x 9.8x 9.3x 6.8x 2.8x 5.0x 3.0x 1.9x 1.4x 1.6x 1.5x 1.5x
Price to Book 7.3x 7.3x 9.7x 13.1x 15.4x 16.6x 6.6x 9.1x 5.4x 3.9x 2.4x 2.7x 2.5x 2.2x
Dividend Yield 0.9% 1.1% 1.3% 1.2% 1.2% 1.6% 2.6% 1.6% 2.5% 1.7% 2.5% 2.3% 2.7% 3.1%
Profitability Ratios
Gross Margin 75.6% 76.4% 79.7% 82.3% 84.0% 84.0% 79.7% 80.5% 77.7% 76.0% 75.4% 75.5% 75.7% 76.1%
EBITDA Margin 29.5% 32.1% 36.9% 38.7% 38.7% 36.5% 26.0% 29.1% 19.9% 18.4% 17.4% 17.7% 18.5% 19.4%
Operating Margin 22.6% 26.1% 31.8% 36.0% 36.2% 33.9% 21.5% 24.4% 14.7% 12.7% 11.8% 11.7% 12.6% 14.1%
Profit Margin 12.1% 21.6% 23.6% 31.9% 26.3% 25.0% 17.7% 18.2% 7.9% 7.0% 7.9% 8.7% 9.5% 11.1%
Return on Assets 11.5% 20.6% 21.6% 31.4% 31.0% 28.7% 16.2% 14.9% 6.1% 5.8% 7.7% 8.7% 9.2% 10.0%
Return on Equity 17.9% 29.1% 28.7% 43.4% 44.0% 52.9% 41.0% 36.2% 14.3% 13.2% 15.1% 16.3% 17.2% 16.7%
Leverage & Coverage Ratios
Current Ratio 2.64 3.42 3.86 2.49 2.67 2.83 2.96 3.16 1.03 1.54 2.24
Quick Ratio 1.96 2.72 3.42 2.08 2.23 2.09 2.54 2.86 0.93 1.29 1.86
Interest Coverage Ratio (EBIT/I) 27.26 28.76 67.10 70.90 132.22 58.89 7.54 8.75 4.81 5.04 13.51
Tot Debt/Capital 0.13 0.00 0.00 0.00 0.00 0.44 0.50 0.43 0.44 0.32 0.23
Tot Debt/Equity 0.14 0.00 0.00 0.00 0.00 0.78 1.00 0.75 0.79 0.48 0.31
Others
Asset Turnover 0.95 0.95 0.92 0.98 1.18 1.15 0.92 0.82 0.77 0.83 0.97
Accounts Receivable Turnover 5.80 5.97 5.97 5.51 5.24 4.81 4.21 4.18 4.28 4.70 5.65
Accounts Payable Turnover 6.34 6.42 6.73 6.19 3.78 3.62 4.37 3.86 6.35 7.92 8.07
Inventory Turnover 2.93 3.14 3.94 3.60 3.16 3.24 3.49 3.98 5.86 5.77 6.44
Effective Tax Rate 37.4% 20.4% 20.7% 17.9% 22.0% 21.6% 31.2% 22.9% 54.5% 28.3% 24.8%
Company Analysis - Financials IV/IV
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |
NOBEL BIOCAR-
REG
STRAUMANN
HLDG-RZIMMER HLDGS
SONOVA HOLDING
ADENTSPLY INTL
SIRONA DENTAL
SY
FRESENIUS
MEDICAWILLIAM DEMANT SMITH & NEPHEW FRESENIUS SE & C
TECAN GROUP AG-
RCELESIO AG GALENICA -REG
12/2012 12/2011 12/2012 03/2012 12/2012 09/2012 12/2011 12/2011 12/2012 12/2011 12/2011 12/2011 12/2011
11.68 160.70 76.75 115.30 43.51 73.98 60.27 596.50 738.00 96.93 90.00 15.57 626.00
27.04.2012 29.05.2012 13.02.2013 15.02.2013 19.02.2013 08.02.2013 30.07.2012 19.07.2012 30.01.2013 16.10.2012 13.02.2013 22.10.2012 11.07.2012
7.09 97.90 57.46 82.23 35.04 40.59 47.79 454.00 567.50 68.60 59.05 10.72 479.25
21.11.2012 16.11.2012 26.07.2012 22.05.2012 02.08.2012 04.06.2012 10.01.2013 16.11.2012 06.06.2012 26.04.2012 06.06.2012 05.06.2012 16.11.2012
1'761'304 97'702 314'095 97'282 218'400 347'910 424'277 88'274 806'940 312'402 15'262 303'411 8'643
9.13 127.00 76.04 113.80 43.14 71.51 51.84 487.50 711.00 88.74 88.15 13.50 539.50
-21.8% -21.0% -0.9% -1.3% -0.9% -3.3% -14.0% -18.3% -3.7% -8.4% -2.1% -13.3% -13.8%
28.8% 29.7% 32.3% 38.4% 23.1% 76.2% 8.5% 7.4% 25.3% 29.4% 49.3% 25.9% 12.6%
122.8 15.5 173.5 66.5 141.7 55.1 304.1 57.6 902.5 163.2 11.4 170.1 6.4
1'130.2 1'990.9 13'193.1 7'600.9 6'122.8 4'063.6 15'865.5 28'445.6 6'432.9 15'815.0 1'008.8 2'296.4 3'506.8
99.5 1.8 1'820.9 257.8 1'766.7 75.5 7'211.4 2'312.0 468.0 10'208.0 4.4 2'067.0 1'165.2
- - - - - - - - - - - - -
- - - 1.8 36.1 3.0 570.0 4.0 - 4'923.0 - 32.2 45.7
154.9 378.0 1'555.9 198.7 77.1 151.1 457.3 288.0 178.0 635.0 165.1 448.3 345.3
860.3 1'874.1 13'458.1 7'648.6 7'754.6 4'018.3 22'364.4 30'530.6 10'127.5 31'578.0 875.8 4'142.0 4'422.8
LFY 580.5 693.6 4'471.7 1'619.8 2'928.4 979.4 12'795.1 8'041.0 4'137.0 16'522.0 377.0 23'026.4 3'480.6
LTM 580.5 688.0 4'471.7 1'729.3 2'928.4 993.6 13'417.2 8'399.0 4'137.0 18'533.0 377.3 22'560.6 3'545.8
CY+1 570.8 694.9 4'612.8 1'839.0 2'996.3 1'086.7 13'734.6 8'673.0 4'408.4 19'233.0 393.0 22'542.0 3'441.6
CY+2 591.7 699.3 4'798.8 1'988.6 3'172.3 1'181.4 14'706.6 9'384.5 4'599.3 20'953.4 425.3 22'562.5 3'558.3
LFY 1.3x 3.0x 2.6x 3.9x 2.4x 3.6x 2.4x 4.1x 2.5x 1.9x 1.5x 0.2x 1.4x
LTM 1.3x 3.0x 2.6x 3.7x 2.4x 3.5x 2.3x 3.9x 2.5x 1.7x 1.5x 0.2x 1.4x
CY+1 1.5x 2.6x 2.9x 4.1x 2.4x 3.6x 2.2x 3.5x 2.2x 1.6x 2.2x 0.2x 1.2x
CY+2 1.4x 2.5x 2.7x 3.7x 2.2x 3.1x 2.0x 3.2x 2.0x 1.4x 1.9x 0.2x 1.1x
LFY 100.7 116.7 1'676.9 366.1 421.6 263.5 2'632.2 1'905.0 1'271.0 3'237.0 60.4 486.6 399.9
LTM 100.7 128.5 1'676.9 416.9 488.9 266.7 2'817.0 - 1'236.0 3'672.0 62.1 597.0 408.2
CY+1 100.9 130.2 1'767.4 462.0 632.9 297.0 2'907.4 1'955.8 1'257.4 3'830.3 63.6 554.7 417.9
CY+2 109.4 156.6 1'846.2 522.1 672.9 330.1 3'114.3 2'260.3 1'365.9 4'161.5 72.3 612.1 421.7
LFY 7.3x 17.7x 7.1x 17.4x 16.7x 13.3x 11.7x 17.2x 8.1x 9.9x 9.6x 8.7x 12.1x
LTM 7.3x 16.1x 7.1x 15.3x 14.4x 13.1x 11.0x - 8.3x 8.7x 9.3x 7.1x 11.8x
CY+1 8.6x 14.0x 7.6x 16.2x 11.4x 13.0x 10.2x 15.5x 7.7x 8.0x 13.4x 7.4x 10.1x
CY+2 7.5x 11.3x 7.0x 14.0x 10.2x 11.1x 9.3x 13.2x 6.8x 7.2x 11.1x 6.4x 9.6x
LFY 0.37 4.54 5.30 3.71 1.99 2.33 3.51 - 0.67 4.18 4.12 0.46 34.46
LTM 0.37 4.91 5.32 4.40 1.94 2.42 4.08 21.23 0.82 5.30 3.63 1.01 36.64
CY+1 0.39 5.27 5.76 5.02 2.45 3.46 3.72 21.12 0.78 5.41 4.06 1.20 37.80
CY+2 0.45 6.75 6.26 5.73 2.72 3.84 4.00 25.90 0.85 5.94 4.86 1.34 39.02
LFY 20.0x 25.9x 14.3x 25.9x 22.2x 29.5x 17.0x 23.0x 13.3x 16.7x 24.3x 13.4x 14.7x
LTM 20.0x 25.9x 14.3x 25.9x 22.2x 29.5x 17.1x - 16.0x 18.7x 24.4x 12.8x 14.8x
CY+1 18.8x 24.1x 13.2x 22.7x 17.6x 20.7x 18.6x 23.1x 13.9x 16.4x 21.7x 11.3x 14.3x
CY+2 16.4x 18.8x 12.1x 19.9x 15.9x 18.6x 17.3x 18.8x 12.8x 14.9x 18.1x 10.1x 13.8x
1 Year 2.0% (6.0%) 0.4% 0.2% 15.4% 7.2% 6.2% 16.7% (3.1%) 3.4% 1.7% (1.1%) 1.0%
5 Year (3.2%) 0.9% 2.0% 8.4% 7.5% 6.8% 7.1% 10.0% 2.3% 11.9% (1.2%) 0.2% 7.4%
1 Year (3.7%) (44.7%) 3.7% (2.0%) - 8.8% 8.5% 17.5% 5.2% 5.9% (6.8%) (26.8%) (9.9%)
5 Year (16.1%) (11.5%) 1.6% 3.7% 2.6% 11.9% 10.7% 6.0% 6.2% 11.9% (0.9%) (9.3%) 21.9%
LTM 17.4% 18.7% 37.5% 24.1% 16.8% 26.8% 21.0% - 29.9% 19.8% 16.4% 2.6% 11.5%
CY+1 17.7% 18.7% 38.3% 25.1% 21.1% 27.3% 21.2% 22.6% 28.5% 19.9% 16.2% 2.5% 12.1%
CY+2 18.5% 22.4% 38.5% 26.3% 21.2% 27.9% 21.2% 24.1% 29.7% 19.9% 17.0% 2.7% 11.9%
Total Debt / Equity % 30.6% 0.3% 31.0% 17.5% 95.6% 7.6% 91.3% 70.1% 12.0% 171.0% 1.6% 81.2% 100.7% FALSE
Total Debt / Capital % 23.4% 0.3% 23.7% 14.9% 48.4% 7.1% 46.0% 41.2% 10.8% 48.4% 1.6% 44.5% 49.2% FALSE
Total Debt / EBITDA 0.988x 0.011x 1.086x 0.604x 3.373x 0.283x 2.996x - 0.379x 3.072x 0.101x 3.317x 2.978x FALSE
Net Debt / EBITDA -0.550x -0.910x 0.158x 0.111x 3.258x -0.183x 2.777x - 0.235x 2.808x -2.143x 3.041x 2.189x FALSE
EBITDA / Int. Expense 19.811x 197.209x 23.003x 61.253x 9.623x 54.441x 7.386x 22.952x 105.917x 5.514x 597.723x 3.093x 10.010x FALSE
S&P LT Credit Rating - - A- - BBB+ - BB+ - - BB+ - - - FALSE
S&P LT Credit Rating Date - - 13.04.2007 - 02.09.2011 - 19.09.2012 - - 19.09.2012 - - - FALSE
Moody's LT Credit Rating - - Baa1 - Baa2 - - - - WR - - - FALSE
Moody's LT Credit Rating Date - - 12.11.2009 - 16.08.2011 - - - - 30.04.2006 - - - FALSE
52-Week High Date
52-Week Low
Latest Fiscal Year:
52-Week High
Total Debt
Market Capitalization
Daily Volume
52-Week Low % Change
Current Price (2/dd/yy)
52-Week High % Change
Cash and Equivalents
EBITDA
EV/EBITDA
Enterprise Value
Valuation
Preferred Stock
52-Week Low Date
Minority Interest
Total Common Shares (M)
P/E
Revenue Growth
Total Revenue
EV/Total Revenue
EPS
EBITDA Growth
EBITDA Margin
Credit Ratings
Leverage/Coverage Ratios
Company Analysis - Peers Comparision
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |
top related